Webinar


The Editor's Roundtable: Current Perspectives on Triglycerides and Atherosclerosis [PDF]

Despite several decades of research about triglycerides and atherosclerotic cardiovascular disease, controversy still surrounds the question whether triglycerides are more than a biomarker and play a direct causative role in atherogenesis. In this Editor's Roundtable, a panel of leading lipid experts addresses this question as well as several closely related issues about triglycerides.

VIEW TRANSCRIPT »

Webinar


VIEW TRANSCRIPT »

Webinar


Hypertriglyceridemia: Diagnosis and Management

This program discusses the emerging role and increasing importance of triglycerides as a predictor of and causal agent of atherosclerotic cardiovascular disease. National Lipid Association goals of therapy and treatment options are discussed, including pharmacologic doses of Omega 3 Fatty Acids.

VIEW PROGRAM »

VIDEO Q&A


Click title to hear audio response

Introduction Current TG Level Designations Prevalence of HTG in NHANES 1999-2008: Overall and by Ethnicity (%) Genetic Causes of Hypertriglyceridemia Most Forms of HTG Are of Secondary Origin Drugs That May Elevate LDL-C or TG Concentrations Components, Size, and Density of Human Serum Lipoproteins Non-HDL-C Includes Cholesterol in All Atherogenic Lipoproteins Lipid Consequences of HTG Mechanisms Why Patients with Elevated TG Levels May Have Increased Risk of CVD Increasing TG Levels Increases CVD and All-Cause Mortality Lower TG Levels Are Associated With Lower CVD Risk Reduced APOC3 Loss-of-Function Mutations Show Reduced CHD Risk TG Level Is an Excellent Predictor of CV Risk in Apparently Healthy Women Genetics: Current Concepts on Relationship between TG, HDL-C, and ASCVD In HTG Subjects, LDL-C Underestimates CVD Risk NLA: Targets of Therapy – Atherogenic Cholesterol NLA: Targets of Therapy – Triglycerides NLA: Treatment Goals for Non-HDL-C, LDL-C, and Apo B National Lipid Association (NLA): Drug Therapy for TG Reduction CardioBrief 4/18/2016: FDA Ends Niacin, Fibrate Combos with Statins Lifestyle and Diet Can Improve Dyslipidemia Risk Difference vs Placebo of HTG Subgroups Primary and Secondary CVD Prevention Trials OM-3 FA Molecular Structure Prescription vs Dietary Supplement OM-3 Continuing Concerns about Dietary Supplements JELIS: EPA Reduced Major Coronary Events in Hypercholesterolemic Patients on Statins JELIS: Larger Decrease in MACE in Those with TG >150 mg/dL & HDL-C <40 mg/dL EPA+Statin Increases Fibrous Cap Thickness and Length Ongoing EPA+DHA and EPA-Only: CVD Outcome Studies In a Meta-analysis of 6 Head-to Head Trials, DHA Significantly Increased LDL-C and HDL-C, and Nonsignificantly Lowered TG Compared to EPA EPA+DHA and Lipid Levels in Patients with TG >500 mg/dL Statin + EPA/DHA: COMBOS Trial EPA: MARINE Trial Lipid Efficacy ANCHOR Study: EPA and Lipid Endpoints Additional Points from the ANCHOR Trial Investigational TG-Lowering Agents Summary

Webinar


Hypertriglyceridemia: Key Concepts and Recommendations: What the Nurse Practitioner Needs to Know

The ongoing nature of Nurse Practitioner/patient encounters places the NP in a unique position to help patients reduce their cardiovascular risk by allowing for the identification and management of risk factors throughout the patient's lifespan. This multimedia program was designed to augment NPs' basic understanding of dyslipidemia and elevated triglycerides with the latest clinical information, including the new National Lipid Association recommendations for aggressive management of all ApoB-containing cholesterol.

VIEW PROGRAM »
  • Program 1

    Hypertriglyceridemia:
    Key Concepts and Recommendations

  • Program 2

    Triglycerides & Non-HDL Cholesterol

MULTIMEDIA PROGRAM


SUGGESTED READINGS


ADDITIONAL RESOURCES